XT
ACRS icon

XTX Topco’s Aclaris Therapeutics ACRS Stock Holding History

XTX Topco’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-97,774
Closed -$367K – 4098
2026
Q1 		$367K Sell
97,774
-15,138
-13% -$51.1K 0.01% 2303
2025
Q4 		$340K Buy
112,912
+48,987
+77% +$124K 0.01% 1957
2025
Q3 		$121K Buy
63,925
+40,008
+167% +$69.8K 0.01% 1983
2025
Q2 		$34K Buy
+23,917
New +$32.4K ﹤0.01% 2085
2025
Q1 		– Sell
-44,685
Closed -$111K – 2340
2024
Q4 		$111K Buy
+44,685
New +$111K 0.01% 1747
2024
Q3 		– Sell
-24,452
Closed -$26.9K – 2026
2024
Q2 		$26.9K Sell
24,452
-98,648
-80% -$116K ﹤0.01% 1583
2024
Q1 		$153K Sell
123,100
-255,200
-67% -$304K 0.02% 1257
2023
Q4 		$397K Buy
+378,300
New +$1.15M 0.09% 405
2023
Q1 		– Sell
-12,423
Closed -$196K – 1228
2022
Q4 		$196K Buy
+12,423
New +$200K 0.04% 851

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

XTX Topco's ACRS Position: Q2 2026 in Review

XTX Topco sold out of Aclaris Therapeutics (ACRS) in Q2 2026, closing a stake of 97,774 shares — an estimated $367K sold.

XTX Topco first reported a position in ACRS in Q4 2022 and held it in 9 quarters. The position peaked at $397K in Q4 2023. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • XTX Topco reported no remaining Aclaris Therapeutics position as of Q2 2026 after selling out during the quarter.
  • XTX Topco sold 97,774 Aclaris Therapeutics shares in Q2 2026, an estimated $367K.
  • XTX Topco first reported a position in Aclaris Therapeutics in Q4 2022 and held it in 9 quarters.
  • XTX Topco's Aclaris Therapeutics position peaked at $397K in Q4 2023.
  • 148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.